ACAD vs SUPN
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare diseases. SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | ACAD | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $24.83 | $47.19 | |
| Market cap as of 2026-07-26 | $4.3B | $2.7B | |
| P/E as of 2026-07-26 | 11.32 | n/a | |
| PEG as of 2026-07-26 | -5.27 | n/a | |
| Net margin as of 2026-07-26 | +34.3% | -3.7% | ACAD higher |
| Gross margin as of 2026-07-26 | +91.5% | +89.7% | ACAD higher |
| Operating margin as of 2026-07-26 | +7.4% | -7.8% | ACAD higher |
| ROE as of 2026-07-26 | +35.6% | -2.7% | ACAD higher |
| ROA as of 2026-07-26 | +26.2% | -2.0% | ACAD higher |
| Debt / equity as of 2026-07-26 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-26 | -13.6% | +16.3% | SUPN higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +2.5% | ACAD higher |
| Beta as of 2026-07-26 | 0.86 | 0.57 | |
| 1-year return as of 2026-07-23 close | +7.8% | +40.6% | SUPN higher |
Fundamentals: Finnhub, as of 2026-07-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.